Welcome to the Newsroom
17 July 2017
Prima BioMed Announces Second Milestone Payment for IMP701 Program
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”) today announced it will receive a second undisclosed significant clinical milestone
payment from Novartis, based on the collaboration and licensing agreement between the
companies, relating to Prima’s IMP701 LAG-3 antibody (also referred to as LAG525).
Article as pdf